XOMA - Lexicon Pharmaceuticals Reports Q1 Loss Misses Revenue Estimates | Benzinga
Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this drugmaker would post a loss of $0.23 per share when it actually produced a loss of $0.20, delivering a surprise of 13.04%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.13 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 3.09%. This compares to year-ago revenues of $0.02 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on ...